Nur Nicholson is CTO at Apellis Pharmaceuticals, Inc. (APLS). They have made 12 open-market trades across 1 company since 2023, most recently 2026-05-14.
CIK 0001827317
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 12 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| APLS | 22,610 | $928K |
Shares reported on the most recent Form 4, priced at the 2026-05-14 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| APLS | SELL | 2026-01-22 | 2026-01-23 | $21.77 | $168K | +7.2% | +4.1% | +89.6% |
| APLS | SELL | 2026-01-20 | 2026-01-21 | $19.79 | $44K | +9.0% | +6.3% | +95.4% |
| APLS | SELL | 2026-01-13 | 2026-01-15 | $22.19 | $58K | +12.4% | +5.1% | +99.0% |
| APLS | SELL | 2025-01-29 | 2025-01-30 | $29.52 | $24K | -5.8% | -20.6% | -36.6% |
| APLS | SELL | 2025-01-22 | 2025-01-23 | $30.43 | $240K | -6.4% | -10.8% | -43.1% |
| APLS | SELL | 2025-01-17 | 2025-01-21 | $29.96 | $129K | -3.4% | -5.6% | -39.9% |
| APLS | SELL | 2025-01-13 | 2025-01-14 | $28.70 | $151K | +5.2% | -3.1% | -31.8% |
| APLS | SELL | 2024-03-13 | 2024-03-14 | $57.56 | $1.3M | +5.4% | -8.0% | -24.1% |
| APLS | SELL | 2024-01-29 | 2024-01-31 | $64.14 | $107K | +6.8% | +0.7% | -30.4% |
| APLS | SELL | 2024-01-22 | 2024-01-23 | $65.00 | $169K | -6.3% | +1.3% | -28.6% |
| APLS | SELL | 2024-01-16 | 2024-01-17 | $66.81 | $248K | -1.8% | +3.3% | -22.2% |
| APLS | SELL | 2023-09-18 | 2023-09-19 | $44.27 | $1.8M | -21.1% | -4.2% | +16.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.